Specifically, in breast cancer, emerging biomarkers such as polo-like kinase (PLK) PLK 2, PLK3, and PLK5 have been validated as significant prognostic indicators through survival analysis utilizing the Kaplan–Meier Plotter database. This evidence concerns the gene PLK3 and breast carcinoma.